Spyre Therapeutics to Participate in Stifel 2024 Virtual Immunology and Inflammation Summit
Spyre Therapeutics, Inc. (NASDAQ: SYRE) will take part in a fireside chat and meet with investors during the Stifel 2024 Virtual Immunology and Inflammation Summit. The summit centers on advances in treating inflammatory bowel disease (IBD), giving Spyre a timely forum to share how its work is moving the field forward.
When and How to Join
Management is scheduled to engage with investors on Wednesday at noon Eastern time. The session format is designed for clear, focused updates—what Spyre is building, why it matters for IBD, and how the team is approaching development. Expect a conversation that speaks to both the science and the strategy, including how the company thinks about efficacy, convenience, and real-world use of its therapeutic approaches.
Focus Areas in IBD
Spyre’s mission is to deliver next?generation treatment options for IBD, a condition that has challenged patients and clinicians for decades. The company’s research draws on cutting?edge antibody engineering, rational therapeutic combinations, and precision medicine to improve outcomes over time. Its investigational pipeline includes candidates targeting the ?4?7, TL1A, and IL?23 pathways—areas selected for their potential to provide durable benefits for people living with IBD.
Webcast Replay Availability
If you’re unable to attend live, a webcast replay will be available for 90 days after the event. This extended window makes it easy to catch up on the discussion—or revisit key points—on your own schedule.
About Spyre Therapeutics
Spyre Therapeutics operates at the forefront of biotechnology with a clear focus: reimagining care for inflammatory bowel diseases through biologics built around patient needs. Grounded in research and informed by clinical realities, Spyre aims to develop therapies that not only advance medical science but also meaningfully improve quality of life for people managing IBD.
Stay Connected
For regular updates as the work progresses, follow Spyre Therapeutics on social media and keep an eye on their ongoing initiatives. You’ll find timely news on programs, presentations, and milestones as they happen.
Frequently Asked Questions
What’s the goal of Spyre Therapeutics’ participation in this investor event?
The company plans to discuss its progress in IBD, outline its development strategy, and speak directly with investors during a fireside chat and related meetings at the Stifel 2024 Virtual Immunology and Inflammation Summit.
When is the session scheduled?
The discussion is set for Wednesday at 12:00 p.m. Eastern time.
How can I watch if I miss the live presentation?
A webcast replay will be available for 90 days after the event, including access through the Spyre investor events website.
What is Spyre Therapeutics developing for IBD?
The pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL?23. The broader approach brings together antibody engineering, rational combinations, and precision medicine to aim for better, longer?lasting patient outcomes.
What’s the best way to stay updated on Spyre’s news?
Follow Spyre Therapeutics on social media for ongoing updates about programs, presentations, and other company initiatives.